Literature DB >> 16183479

Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.

Nazmi Volkan Adsay1, Olca Basturk, Jeanette D Cheng, Aleodor A Andea.   

Abstract

Most pancreatic neoplasia are of ductal lineage, characterized by tubule (gland), cyst, papilla, or mucin formation and expression of mucin-related glycoproteins and oncoproteins (eg, MUC1, CA19-9, CEA, DUPAN), as well as some subsets of cytokeratin (eg, CK19). Mutations of k-ras oncogene and DPC4 are also common in ductal neoplasia and generally not seen in nonductal tumors. A variety of pancreatic neoplasia fall under the heading of ductal neoplasia. Invasive ductal adenocarcinoma (DA) is the most important and constitutes the vast majority (>85%) of pancreatic tumors. DA is characterized by insidious infiltration and rapid dissemination, despite its relatively well-differentiated histologic appearance. In some variants of DA such as undifferentiated or sarcomatoid, evidence of ductal differentiation may be lacking or only focal. The presumed precursors of DA are microscopic intraductal proliferative changes that are now termed pancreatic intraepithelial neoplasia (PanIN). PanINs comprise a neoplastic transformation ranging from early mucinous change (PanIN-1A) to frank CIS (PanIN-3). A similar (in situ) neoplastic spectrum also characterizes intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, which are cystic ductal-mucinous tumors with varying degrees of papilla formation, and may be associated with invasive carcinoma. As such, these can be regarded as mass-forming preinvasive neoplasia. Some intraductal papillary mucinous neoplasms are associated with invasive carcinoma of the colloid type. Colloid carcinoma of the pancreas appears to be a clinicopathologically distinct tumor with indolent behavior. Whereas most ductal pancreatic neoplasia are characterized by some degree of mucin formation, serous tumors, of which serous (microcystic) adenoma is the sole example, lack mucin formation, presumably because they recapitulate centroacinar ducts. They are typically benign tumors. It is recognized now that pancreatic carcinoma, like other malignant processes, is a genetic disease produced by progressive mutations in cancer-related genes. These alterations can be categorized as "early" such as k-ras mutation, HER-2/neu, PSCA, MUC5, and fascin overexpression; "intermediate" such as p16 inactivation, MUC1, and cyclin D1 overexpression; and finally as "late" such as p53 and DPC4 inactivation, BRCA2 mutation, and overexpression of ki-67, 14-3-3sigma, and mesothelin. Ductal neoplasia is the most important category among pancreatic tumors. It is important to appreciate the different types of ductal tumors because they vary greatly in their clinicopathologic characteristics and prognosis. Understanding the molecular mechanisms of ductal carcinogenesis will help develop more efficient prevention and therapy of these tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183479     DOI: 10.1016/j.semradonc.2005.04.001

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  12 in total

1.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

2.  Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.

Authors:  Dahlia M Besmer; Jennifer M Curry; Lopamudra D Roy; Teresa L Tinder; Mahnaz Sahraei; Jorge Schettini; Sun-Il Hwang; Yong Y Lee; Sandra J Gendler; Pinku Mukherjee
Journal:  Cancer Res       Date:  2011-05-10       Impact factor: 12.701

Review 3.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.

Authors:  Andrés J Muñoz Martín; Pilar García Alfonso; Ana B Rupérez; Miguel Martín Jiménez
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

Review 5.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

6.  MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.

Authors:  Nils Habbe; Jan-Bart M Koorstra; Joshua T Mendell; G Johan Offerhaus; Ji Kon Ryu; Georg Feldmann; Michael E Mullendore; Michael G Goggins; Seung-Mo Hong; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2009-02-03       Impact factor: 4.742

7.  MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.

Authors:  Jin Wang; Jinyun Chen; Ping Chang; Aimee LeBlanc; Donghui Li; James L Abbruzzesse; Marsha L Frazier; Ann M Killary; Subrata Sen
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-01

8.  Association between genetic subgroups of pancreatic ductal adenocarcinoma defined by high density 500 K SNP-arrays and tumor histopathology.

Authors:  María Laura Gutiérrez; Luís Muñoz-Bellvis; María del Mar Abad; Oscar Bengoechea; María González-González; Alberto Orfao; José María Sayagués
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

9.  Purified human pancreatic duct cell culture conditions defined by serum-free high-content growth factor screening.

Authors:  Corinne A Hoesli; James D Johnson; James M Piret
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

10.  MUC1 regulates PDGFA expression during pancreatic cancer progression.

Authors:  M Sahraei; L D Roy; J M Curry; T L Teresa; S Nath; D Besmer; A Kidiyoor; R Dalia; S J Gendler; P Mukherjee
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.